Events and conferences
PEGS Summit Europe
Network with 1,200+ colleagues at PEGS Europe, the largest protein & antibody engineering event in Europe, which has been described as “the best biologics technology meeting in Europe.” Last year, nearly 900 delegates from 35 countries, including 78% from pharma and biotech organizations, convened in beautiful Barcelona and online to discuss the latest advances in protein and antibody engineering.
Unlocking the Potential of mRNA as a Tool for Immuno-Oncology Therapy Discovery and Development
Immuno-oncology is a rapidly growing area for therapeutic development. With the adoption of various autologous cell therapies and an increased focus on more broadly applicable allogeneic treatments and multi-specific therapies, the complexity of these development activities is also increasing. With this drive to increased complexity and the inherent risks associated with potential failure in Phase 1 clinical trials, it is critical to have a solid scientific foundation for the development of these next-generation immunotherapies. This talk will focus on how to overcome the limitations associated with traditional viral vector based recombinant TCR gene expression to build hundreds of candidates a week, resulting in improved confidence in screening and lead optimization. With the direct use of mRNA to drive transient modulation of cellular phenotypes, potential candidates can be screened quickly and cost-effectively. Come and learn how immuno-oncology researchers are automating synthetic biology on-site to unlock speed and efficiency in adoptive T-cell therapies and vaccine discovery workflows.
Accelerating antibody discovery with cell-free DNA synthesis
Developing antibody therapeutics requires screening large pools of candidate antibodies expressed from DNA constructs. Building these DNA constructs involves multiple arduous steps, including synthesizing lead candidate genes, cloning them into vectors, and amplifying plasmids in Escherichia coli cells. Recent strides in synthetic biology and automation have enabled researchers to efficiently generate synthetic DNA products in vitro. In this webinar brought to you by Telesis Bio, Jasmine Hershewe will discuss a cell-free platform that automates DNA printing, cloning, and amplification, expediting the screening and identification of lead antibody candidates.
Antibody Engineering Therapeutics
The #1 Antibody engineering conference for accelerating next generation antibodies to commercial success. The latest science and research on antibody engineering, design and selection diving into critical topics including Neurodegenerative Diseases, Tumor Microenvironment in Antibody Therapy, Antibody Immune Agonist, Bi-Specifics, ADCs, Protein-Based Degraders, Immuno-oncology, T-Cells, VHH and much more.